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ABSTRACT

Systemic Lupus Erythematosus (SLE) is an autoimmune disorder that can affect every
tissue in the body. Single nucleotide polymorphisms (SNPs) in the IRF5 and TNPO3
genes are statistically associated with the development of SLE. My research identified
correlations between IRF5/TNPO3 SNPs and specific lupus symptoms. Logistic
regression analyses were conducted using 101 genetic variants in the IRF5/TNPO3 region
that were genotyped in over 6,000 lupus patients of different ethnicities, with admixture
covariates applied. Three clinical phenotypes displayed significant correlation (p <
1.6x10-5) in subjects of European ancestry. For each of these phenotypes, a step-wise
conditional analysis was conducted using two lupus associated single nucleotide
polymorphisms (SNPs) at this genetic loci. In Europeans, lupus disease onset (pvalueEU=2.44x10-16, OR=0.67*) and the presence of anti-Ro (p-valueEU=2.09x10-7,
OR=0.67) and anti-dsDNA (p-valueEU=4.15x10-7, OR=0.75) antibodies were associated
with SNPs in the IRF5/TNPO3 genes. SNPs in the IRF5 promoter and those spanning
IRF5 and TNPO3 were both associated with disease onset. The presence of anti-Ro and
anti-dsDNA antibodies is only associated with SNPs in the IRF5 promoter. Genetic
variants at the IRF5/TNPO3 locus are associated with lupus disease onset and production
of anti-dsDNA and anti-Ro antibodies in lupus patients. SNPs in the promoter region of
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IRF5 (associated with rs4728142) and SNPs spanning the IRF5 and TNPO3 genes
(associated with rs12534421) contribute independently to these symptoms.

Keywords: Lupus, IRF5, serology, sub-phenotype, SNP
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Dedicated to Derick Strode, who inspired me to try research in the first place.
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CHAPTER 1

PREFACE

During the summer of 2012, I was selected to be one of 120 students involved in a
Summer Undergraduate Research Fellowship at Cincinnati Children’s Hospital. It was a
ten week, paid internship where students conducted research in the extensive research
facilities of the third best children’s hospital in the nation. Students in this program were
placed in laboratories addressing almost every health issue available, from cancer to
development to x-ray imaging and cardiac diseases. Because of my prior experience in
bioinformatics analysis, I was chosen to analyze the genetic data of lupus patients in the
rheumatology department.
Systemic Lupus Erythematosus (SLE or lupus) is a systemic autoimmune disorder
that can affect every tissue in the human body. The body’s immune system is designed to
differentiate between self (cells of the body) and non-self (cells from the outside world,
which could possibly be harmful). When functioning correctly, immune cells attack nonself cells while ignoring self cells. However, in an autoimmune disease like SLE, the
immune system begins attacking the cells of the body.
Lupus is a heterogenous disease that can look very different in different people.
There is no laboratory test for lupus, instead, there are eleven criteria that lead to a
clinical diagnosis of lupus. Any four of the eleven must be manifested for a lupus
diagnosis according to the American College of Rheumatology. They are: hematologic
1

Lymphopenia
Hemolytic Anemia
Hematologic
Disorders
Leucopenia
Discoid Rash
Thrombocytopenia
Malar rash
Pleuritis
Serositis
Pericarditis
proteinuria
Renal Disorders
cellular cast
seizure
neurologic
disorders
psychosis
SLE criteria

Oral ulcer
LE cell
Immunologic
disorders

Arthritis

Lupus
anticoagulant
false positive
VDRL
Anti-dsDNA

Photosensitivity
Anti-ro
Anti-p
Antinuclear
antibodies
Anti-sm
Anti-la
Anti-nrnp

Figure 1. A chart of the thirty phenotypic characteristics of SLE. The bold items are the eleven main
criteria defined by the American Rheumatology. In addition to these thirty characteristics, the age of
onset of lupus symptoms was also studied.
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(blood) disorders (anemia, leukopenia, lymphopenia, or thrombocytopenia), discoid rash,
malar rash, serositis (inflammation of the lining around the lungs or heart),
photosensitivity, renal (kidney) disorders, arthritis, neurologic disorders, oral ulcers,
immunologic disorders (presence of certain autoantibodies, and abnormal antinuclear
antibodies. These 11 symptoms have been broken into 30 subgroups, for which clinical
data can be collected in lupus cases and controls (Figure 1). To study the genetic
determinates of these sub-phenotypes, we used data from the Large Lupus Association
Study 2 (LLAS2). Twenty-four different investigators contributed samples of DNA in
addition to clinical information. Altogether, the LLAS2 dataset contained genetic and
phenotypic data of over 6,000 people with lupus collected by researchers around the
globe. Data from subjects of four different ancestral origins was studied: European
American, Hispanic, African American, and Asian American (Figure 2). For each
ancestry, covariates were calculated to account for admixture. Admixture is the concept

SLE Case Ethnicities
Asian
16%

Hispanic
16%

European
49%

African-American
19%

European

African-American

Hispanic

Asian

Figure 2. Percentage of cases of different ethnicities analyzed from the LLAS2 data set.
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that individuals are rarely ever purely one race, but instead have a genetic history from
multiple ancestries. The covariates determine and account for mixed genetics in each
individual in the study.
Single Nucleotide Polymorphisms (SNPs) are variations in the genome that occur
at a single base pair. These genetic variants are manifested in at least 5% of the
population. The variations can be silent, causing no change in the gene’s protein
structure, or they can change the promoter region, causing the gene to be over or under
expressed, or the amino acid sequence, impacting the entire function of the resulting
protein.
There is no clearly defined single cause of lupus onset, rather, it is a result of both
environmental and genetic causes. SNPs in over 45 genes have been repeatedly
associated with lupus development, or etiology. Two of the most commonly associated
loci includes the Interferon Regulatory Factor 5 (IRF5) gene and the nearby Transportin 3
(TNPO3) gene. The IRF5 gene is especially noteworthy because it regulates chemicals
called interferons. Interferons act as signals in the body that activate the immune response
to viral infections. In lupus, interferons have been demonstrated to drive the autoimmune
response and the pathology of SLE. In the LLAS2 study subjects, 101 genetic variants
were genotyped in the IRF5/TNPO3 gene region. Case-control analysis of these SNPs
showed significant association with lupus development. In fact, the group at the
Cincinnati Children’s Hospital established that there are SNPs that are highly associated
with lupus development in the promoter of IRF5 and in a region spanning the IRF5 and
TNPO3 genes (p-value of less than 10-8).

4

Figure 3. SNP locations in reference to the IRF5 and TNPO3 genes. The black bars show the gene
locations, and the two gray boxes are two groups of SNPs that are in high linkage within the gray
region, but display little association with the other SNP group. The relative locations of SNPs
connected to SLE symptoms are shown.

SNPs in a certain area tend to be found together, an occurrence known as linkage
disequilibrium (LD). In the case of lupus development, the most associated SNPs are
located in the promoter region of IRF5, and were closely linked with each other (Figure
3). When the association of the SNP with the lowest p-value (rs4728142, located in the
promoter of IRF5) was accounted for in a conditional analysis, the only remaining
genetic association was found in a group of SNPs that span the IRF5 and TNPO3 genes.
Upon further conditional analysis, removing the association of the next-most associated
SNP (rs12534421) caused all association to be eliminated. This suggested that all
significant association with lupus development was linked with two main SNPs in the
IRF5/TNPO3 area.
Although studies have shown the association of SNPs in the IRF5 locus with
lupus development, there has been little analysis of the possible association with specific
symptoms in lupus. My research sought to identify correlations between SNPs and the
development of lupus sub-phenotypes. I used the statistical software package PLINK
version 1.07 to analyze the LLAS2 data. PLINK is designed to perform in-depth analyses
of SNP associations, and it enabled me to conduct a sub-phenotypic logistic regression
analysis (see Chapter 3) of SNPs in the IRF5/TNPO3 region, identifying connections
5

between displayed lupus symptoms and the SNPs present in this gene area. After
formatting the data appropriately and including covariates to account for differences in
genetic admixture, we determined the p-value for each SNP’s association with every
clinical phenotype. In a logistic regression, the p-value gives the probability that the
frequency of the minor allele of a SNP is the same in the people with a sub-phenotype,
such as the people with anti-dsDNA, and the people without the sub-phenotype. The
logistic regression analysis was first done on subjects of European ancestry, then on
Asians, African Americans, and Hispanics. The accepted alpha error rate is 0.05, but
because we performed many independent tests, a multiple testing correction had to be
used. This correction takes into account the number of SNPs compared, as well as the
number of clinical phenotypes analyzed. Using this correction, a significant p-value was
determined to be 1.6x10-5.
In European Americans, the logistic analysis identified three sub-phenotypes that
were significantly associated with SNPs in and around the IRF5/TNPO3 genes (p-value
less than 1.6x10-5). These were the age of onset of lupus (how old a person is when they
develop lupus), the presence of anti-Ro autoantibodies, and the presence of anti-dsDNA
autoantibodies. Anti-Ro autoantibodies target the Ro ribonucleoprotein, which is
normally found in the nucleolus of the cell, while anti-dsDNA autoantibodies target
double stranded DNA (dsDNA). These autoantibodies are not normally formed in
absence of an autoimmune response. In African Americans and Asian Americans, there
was a statistically significant association to age of onset, but not to the other symptoms.
A conditional analysis (see Chapter 3) was conducted for each of the three
statistically associated symptoms, similar to the conditional analyses that demonstrated
6

the two independent SNP groups that were associated with SLE development. This
analysis revealed an association with specific SNPs in the IRF5/TNPO3 area. For age of
onset of lupus, there was a statistically significant association with the SNP rs12534421.
Nearly all phenotype association was removed when the impact of this SNP and all
associated variants were removed in the analysis. When the symptom association with the
next significant SNP, rs4728142, was removed, no SNP association with the age of onset
remained. This demonstrated that all associated SNPs were linked to SNPs rs4728142
and rs12534421.
For the presence of anti-Ro and anti-dsDNA autoantibodies, the conditional
analysis showed association to rs4728142, the primary variant associated with SNPs in
the promoter region of IRF5. After conditioning on (removing the impact of all SNPs
associated with) rs4728142, there was still association with a few SNPs spanning IRF5
and TNPO3 genes (those variants in linkage disequilibrium with rs12534421), but most
of the association was with genetic variants in the promoter.
The fact that different groups of SNPs in the IRF5/TNPO3 region were
statistically associated with the development of different lupus symptoms provides
support to the theory that there are two independent groups of variants in this region, and
that they play separate roles in the development of SLE. This will allow future studies to
specifically focus on the IRF5/TNPO3 region. My results also support previous studies of
these two SNP groups and could refine the study of the biological processes that are
impacted by these variants by directing the focus towards each of the SNP groups
separately.

7

Additionally, our work to identify variants associated with the development of
specific symptoms in people with lupus has immediate therapeutic implications. Lupus is
a relatively rare disease, and doctors are unlikely to prophylactically treat healthy people
who are genetically predisposed to lupus. Once people have lupus, however, there are
different therapeutic options that vary in their aggressiveness. This study may also
contribute to the type of personalized medicine that is the future of health care.
At the end of the summer, I was able to present my research at the University of
Cincinnati’s Undergraduate Research Symposium, where I earned an honorable mention.
In January 2013, I returned to the Rheumatology Department to complete additional data
analyses, instruct a new graduate student in programming with PLINK, and assemble
cohesive, straightforward instructions for future sub-phenotypic, conditional analysis
research in this field.
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CHAPTER 2

INTRODUCTION

Systemic Lupus Erythematosus (SLE or lupus) is an autoimmune disorder
affecting every organ in the body [1]. Patients must display four of eleven clinical
findings for official diagnosis according to the American College of Rheumatology [5, 6].
One in every 5,000 people will be diagnosed with lupus, with 90% of them being female
(Figure 3). African Americans and Asians are three to four times more likely to develop
lupus than persons of European descent, and African American, Asian, and Hispanic
ancestries have a greater mortality rate from this disease [2-4]. Without sophisticated
medical care, SLE has a 50% mortality rate [7].
Genetic factors play a significant role in the etiology of lupus [8]. Previous studies
have demonstrated the effect of genetic variants on the development of specific
symptoms in lupus patients [9-15]. The Interferon Regulatory Factor 5 (IRF5) functions
within the interferon inflammatory pathway and is critical for lupus pathogenesis [15-19].
Single nucleotide polymorphisms (SNPs) within the IRF5 and the nearby Transportin 3
(TNPO3) genes are highly associated with the etiology of lupus, but genetic variant
associations with specific clinical phenotypes of SLE have not yet been identified [2036]. Prior studies indicate that genetic association occurs through two independent
groups of linked SNPs at the IRF5/TNPO3 locus [37]. Variants in the promoter region are
present across ancestries and are accounted for by the rs4728142 SNP, while variants
9

spanning the IRF5/TNPO3 region are present only in populations with European
admixture and are strongly linked to the SNP rs12534421.
The purpose of this study was to determine if either of these two genetic effects at
the IRF5/TNPO3 locus are statistically associated with specific clinical phenotypes in
patients with lupus. The study also investigated how sub-phenotypic associations in
IRF5/TNPO3 vary across different ancestries. Our data indicate that the two effects are
independently associated with three different lupus phenotypes in European Americans,
but only one effect is evident in African Americans, Asians, and Hispanics.
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CHAPTER 3

MATERIALS AND METHODS

Subjects
The study included 3,926 European, 1,257 Asian, 1,287 Hispanic, and 1,524
African-American SLE patients, all of whom met the American College of
Rheumatology (ACR) SLE classification criteria. Phenotypic data and patient DNA were
collected with informed consent and IRB approval by several institutions around the
globe. Thirty-one clinical phenotypes were analyzed, each of which fall into one of the
following categories: age of onset of lupus, presence of certain autoantibodies, false
positive syphilis test, discoid rash, malar rash, renal disorders, neurologic disorders, oral
ulcers, photosensitivity, and hematologic disorders.
Genotyping
Patient DNA was genotyped on an iSCAN array genotyping instrument using the
Illumina custom bead system. One hundred and one lupus susceptibility loci in the
IRF5/TNPO3 region were identified for each patient. SNPs were located in a 437,000
base pair region, ranging from 167 kbp upstream of IRF5 to 61 kbp downstream of
TNPO3. Admixture markers, which indicate ancestral origins, were genotyped and
analyzed for each sample to determine admixture from five ancestries: European
American, African American, Asian and Asian American, and Hispanic American [3841].
11

Statistical analysis
Two main types of analyses were used in this study. The first was a logistic
regression analysis of all SLE symptoms. This analysis compared the presence of
different risk alleles with the presence of each symptom, identifying any association. It
then determined a p-value, which was the probability that the observed association could
randomly occur. The logistic regression served to identify lupus symptoms for which
SNPs in the IRF5/TNPO3 region were significantly associated.
A sub-phenotypic logistic regression analysis was conducted using PLINK
version 1.07, a program designed to analyze SNPs and their associations with phenotypic
data. Admixture covariates were included in the program to account for variances in
ancestry and each ancestry was individually assessed. Using the most stringent
Bonferroni multiple testing correction (p = 0.05/(number of variants x number of
phenotypes) = 0.05/(101 x 31)), a significant p-value was determined to be 1.6x10-5.
Additional label-swapping iterative permutation testing showed that empirically
significant p-values for each SNP are actually closer to 10-4. This test swaps the symptom
affectedness status (from unaffected to affected, or vice versa) for a random selection of
patients, and checks to see if SNP association still exists. It repeats this process several
thousand times, and uses the results to calculate the probability of SNP association
randomly occurring. The sub phenotypic logistic regression analysis of lupus patients
identified three symptoms with significant p-values. The additional permutation testing
confirmed that no other symptoms were significantly associated.
Aside from the logistic analysis, the second main test used in this study is a
conditional analysis. This test determines how many SNPs are actually associated with a
12

specific symptom. For a single symptom, this analysis removes the most associated SNP,
and all of the SNPs that are linked with it. It is then possible to see if any SNPs not
connected with the first SNP are associated with the symptom. For a step-wise
conditional analysis, the symptom is “conditioned” (the association is removed) for the
most associated SNP, followed by the next remaining SNP, then both SNPs
simultaneously, in a series of steps that result in the removal of all significant SNP
association. The conditional analysis shows the top two most associated SNPs that are not
linked to each other. It could be used to identify more associations, but after the
association of the top two are removed, very little SNP association remains.
A conditional analysis was conducted in PLINK v 1.07 to determine which SNPs
were statistically associated with these three phenotypes [42]. Phenotypic associations
were conditioned step-wise using the SNPs that account for the two linked SNP groups in
the IRF5/TNPO3 area: the SNP rs4728142, which is associated with genetic variants in
the promoter region of IRF5, and the SNP rs12534421, which is associated with variants
spanning IRF5 and TNPO3. In cases where the SNPs most associated with lupus
development differed from those most associated with the specific symptoms, the SNPs
most associated with the symptoms were used for the conditional analysis. This was the
case for anti-Ro and anti-dsDNA. In these cases, conditional analyses were conducted
with the two main SNPs for lupus development in addition to the two most associated
symptomatic SNPs.
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CHAPTER 4

RESULTS

The three clinical phenotypes that demonstrate statistically significant association
with variants in IRF5 and TNPO3 are: age of onset of lupus (p valueEU = 2.44x10-16, Odds
Ratio = 0.67*), the presence of anti-Ro antibodies (p valueEU = 2.09x10-7, Odds Ratio =
0.67), and the presence of anti-dsDNA antibodies (p valueEU = 4.15x10-7, Odds Ratio =
0.75). Of the three phenotypes, age of onset of lupus was the only one that was
significantly associated across all three ethnicities (European American, African
American, and Asian). Testing revealed no genetic association with any symptom in
Hispanics. The presence of anti-Ro antibodies was associated with variants in Europeans
only, and the presence of anti-dsDNA antibodies displayed SNP association in Europeans
and African Americans. In Europeans, the SNP rs3778752 had the lowest p value for the
presence of both anti-Ro and anti-dsDNA antibodies. For age of onset of lupus, the SNP
rs4728142 was most significantly associated in both African Americans and Asians, but
not in Europeans.
For all three phenotypes, genetic variant association was no longer significant
when the phenotypic association resulting from the two most associated SNPs was
removed. With age of onset, the group of SNPs spanning IRF5/TNPO3 (closely linked to
the SNP rs12534421) and the group of genetic variants in the promoter region of IRF5
(closely linked with the SNP rs4728142) have significant association in Europeans, with
14

variants linked to rs12534421 having the lowest p values (Figure 4). This is
shown by the sharp decline in statistical significance (-log p value) when each SNP is
conditioned separately. For the presence of anti-Ro and anti-dsDNA antibodies, the
promoter group (rs4728142 and associated SNPs) had the greatest effect (Figures 5-6).
Although rs4728142 and rs12534421 are most closely associated with the
development of lupus and the two genetic effects in the IRF5/TNPO3 region, rs3778752
was most closely linked to the presence of anti-Ro and anti-dsDNA antibodies. The
rs3778752 risk allele is a part of the SNP group in the promoter region of IRF5. In
association studies, rs3778752 had lower p-values than rs4728142 in both anti-dsDNA
(prs37778752 = 4.154 x 10-7, prs4728142 = 5.85 x 10-6) and anti-Ro (prs37778752 = 2.09*10-7,
prs4728142 = 9.37 x 10-7). We identified chromosomes in European Americans in which the
two SNPs segregate (n = 1992) and the subjects have either anti-dsDNA or anti-Ro
antibodies (n = 624). Our results show that subjects with anti-Ro or anti-dsDNA
antibodies are 133% more likely to have the rs3778752 risk allele than the rs4728142 risk
allele.
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Age of Onset

A

B

C

D

Figure 4. Conditional analysis of age-of-onset phenotype. The horizontal bars show the position on
chromosome 7 of IRF5 and TNPO3.The most associated SNPs are identified in A, B, and C. Graph A
shows the statistical significance (-log10[p-value]) of each SNP in the IRF5/TNPO3 region. For graphs B
and C, we removed each of the top two most associated SNPs. Graph D removes the association of both
SNPs. From this, we conclude that rs12534421 (the second group of linked SNPs) is responsible for most
of the statistical association between genetic variants and the age of onset of lupus. When the contribution
of both SNPs is removed, no association remains p<0.01 (D).
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Anti-Ro

A

C

B

D

Figure 5. Conditional analysis of the presence of anti-Ro antibodies. Graph A shows the statistical
significance (-log10[p-value]) of the association of each SNP in the IRF5/TNPO3 region with the presence
of anti-Ro antibodies. For graphs B and C, we removed the association of the two most significant SNPs
(which did not include rs4728142 or rs12534421) separately. The bottom graph removes the association of
both SNPs. From this, we can conclude that rs3778752 (the first SNP group) is responsible for most of the
statistical association of genetic variants with the presence of anti-Ro antibodies.
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Anti-dsDNA

A

B

C

D

Figure 6. Conditional analysis of the presence of anti-dsDNA antibodies. Graph A shows the significance
(-log10[p-value]) of the association of each SNP in the IRF5/TNPO3 region with the presence of antidsDNA antibodies. For graphs B and C, we conditioned separately on the two most closely associated
SNPs. Graph D adjusts for the association of both SNPs. From this, we can conclude that rs3778752 (the
first SNP group) is responsible for most of the statistical association of genetic variants with the presence of
anti-dsDNA antibodies.
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CHAPTER 5

DISCUSSION

Genetic Variant Association
Defined connections between genetic variants and lupus sub-phenotypes may
enable increased understanding of the etiology of lupus. These connections may also
allow clinical practitioners to predict a patient’s risk of developing specific symptoms. In
this study, variants in IRF5 and TNPO3 that are already known to be statistically
associated with the development of lupus were shown to be connected with specific sub
phenotypes including age of onset of lupus and the production of anti-Ro or anti-dsDNA
antibodies. Association was found largely in European American subjects but was also
present in African Americans and Asians to a lesser degree.

Two Independent Genetic Effects
Although the two groups of linked SNPs in IRF5 and TNPO3 are highly
associated with the development of lupus, genetic variants in the promoter of IRF5
(linked to the SNP rs4728142) and genetic variants spanning IRF5 and TNPO3 (linked to
the SNP rs12534421) are independently associated with specific symptoms of lupus. This
supports the hypothesis that these are indeed two separate SNP groups which play
different roles in SLE. The group spanning IRF5/TNPO3 only displays significance in
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European Americans, while the promoter group plays a role in all ethnicities. This
could signify that SNPs in the promoter of IRF5 are part of an ancient set of variants,
while the group of associated SNPs spanning IRF5 and TNPO3 are the result of more
recent variation.

SNP Association Differences
The rs3778752 risk allele shows 133% more association with the presence of antiRo and anti-dsDNA antibodies than the rs4728142 risk allele. Our results suggest that
although rs4728142 is one of the most significant indicators of lupus risk, rs3778752
seems to be far more effective in predicting the production of anti-Ro and anti-dsDNA in
the body.

Conclusion
In conclusion, our study shows that genetic variants in the IRF5/TNPO3 genes are
associated with specific clinical phenotypes of lupus. The two independent SNP groups
in this region function separately in the different symptoms as well as in the different
ethnicities. Our data support prior findings that the two etiological effects are associated
with different ancestries, and indicate that genetic variant groups in IRF5/TNPO3
function differently in the development of certain lupus phenotypes.
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